Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Aethlon Medical Inc.AEMD · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $6.3M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Jun 10, 2026121 days before the rescan; every figure keyed to the SEC receipt date
Last close$6.052026-10-07; market equity $4.3M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$200$400NovDecJanFebMarAprMayJunJulAugSepOct$6.01
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Jul 21, 2012nonen/aQ1
Jul 21, 2022nonen/aQ2
Jul 21, 2024nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Jun 10, 2026; the document on sec.gov.

the context otherwise requires, references to the “Company”, “Aethlon”, “we”, “us” and focused on developing the Hemopurifier® (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 9069.3%[3-4]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 75.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(2.2%)[1,5-7](6.6%)75.48112026-03-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 70.3
Twelve-month failure probabilitynot computable0.07%
four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime(90.06)[1,8-13](0.31)94.07562026-03-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio3.85x[8-9]2.96x46.78392026-03-31
Growth and financing, sleeve percentile 95.7
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(28.7%)[1,7,14-15]2.1%92.27042026-03-31
Net share issuance, one year9,069.3%[3-4]2.5%99.26342026-06-08

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-07 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(99.4%)8.0%0hotter than 0 of 100 peers
Distance from 52-week high(98.4%)(31.4%)0closer to its high than 0 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(163.8%)(1.0%)4pricier than 96 of 100 peers
Book value to price1.220.2891pricier than 9 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years752.4%20.3%99more equity-funded than 99 of 100 peers
Relative strength against the sector, log excess return(5.41)(0.14)0ahead of 0 of 100 peers

Inputs: market equity $4.3M; EBIT -$7.3M; free cash flow -$7.0M; book equity $5.2M; sales $0; cash $4.9M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2026-03-31
Return on assets above zero(97.2%)✗ fail[5,7]
Operating cash flow above zero-$7.0M✗ fail[6]
Return on assets improved65.2 pts✓ pass[5,7,14,17]
Operating cash flow exceeds net income$153,077✓ pass[5-6]
Long-term leverage felln/a[1,7,14]
Current ratio improved71.7 pts✓ pass[8-9,18-19]
No new shares issued9,069.3%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[7,14]
Cash, filings, liquidity
Cash and equivalents$4.9M[20]
Operating cash flow, four quarters-$7.2M[6,20-24]
Months of runway8.2
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$158,580
63 sessions
Days since newest grade input121

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$6.3M2026-03-312026-06-1010-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$02024-03-312024-06-2710-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding2,370,5602026-06-082026-06-1010-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding2,585,3162025-06-242025-06-2610-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$7.2M2026-03-312026-06-1010-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$7.0M2026-03-312026-06-1010-Kfiling · viewer · series
7assetsus-gaap:Assets$7.4M2025-03-312026-06-1010-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$5.6M2026-03-312026-06-1010-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$1.4M2026-03-312026-06-1010-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$175.1M2026-03-312026-06-1010-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$7.3M2026-03-312026-06-1010-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$4.9M2026-03-312026-06-1010-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$1.4M2026-03-312026-06-1010-Kfiling · viewer · series
14assetsus-gaap:Assets$8.2M2024-03-312025-06-2610-Kfiling · viewer · series
15assetsus-gaap:Assets$17.5M2023-03-312024-06-2710-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding711,1362026-08-102026-08-1310-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$13.4M2025-03-312026-06-1010-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$5.9M2025-03-312026-06-1010-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$1.9M2025-03-312026-06-1010-Kfiling · viewer · series
20cashus-gaap:CashAndCashEquivalentsAtCarryingValue$4.9M2026-06-302026-08-1310-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.9M2026-06-302026-08-1310-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.2M2025-12-312026-02-1210-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.4M2025-09-302025-11-1210-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.7M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.